Each new and amended claim is supported by the application as originally filed. Support for amended claim 7 is found on page 8, lines 5-15.

New claims 28-39 are supported by the present specification as filed, on page 3, lines 5-23; page 11, line 30, to page 14, line 22; page 15, lines 13-21; example 5, and the abstract.

Claims 1, 3, 5, 7-15 and 28-39 are now pending in the subject application.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "Version With Markings to Show Changes Made".

Respectfully submitted

Randolph N. Mohr

Registration No. 45,590

Immunex Corporation Law Department 51 University Street Seattle, WA 98101

Telephone: (206) 587-0430 Facsimile: (206) 233-0644

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of:

Docket No.: 2814-G

M. Patricia Beckmann and Douglas P. Cerretti

Serial No.:

--to be assigned--

Filing Date:

July 12, 2001

For:

CYTOKINES THAT BIND THE CELL SURFACE RECEPTOR HEK

# **For Prior Application**

Examiner: P. Mertz Art Unit: 1646

### **VERSION WITH MARKINGS TO SHOW CHANGES MADE**

### In the Specification:

This application is a divisional of application Serial No 09/358,734, filed July 21, 1999, currently allowed, which is a divisional of application Serial No 09/057,121, filed April 8, 1998, now U.S. Patent 5,969,110, which is a divisional of application Serial No. 08/453,943, filed May 30, 1995, now U.S. Patent 5,738,844, which is a divisional of application Serial No. 08/240,124, filed May 9, 1994, now U.S. Patent 5,516,658, which is a continuation-in-part of application Serial No. 08/161,132, filed December 3, 1993, eurrently pending now abandoned, which is a continuation-in-part of application Serial No. 08/114,426, filed August 30, 1993, eurrently pending, now abandoned, which is a continuation-in-part of application Serial No. 08/109,745, filed August 20, 1993, eurrently pending now abandoned,

#### In the claims:

Please cancel claims 2, 4, 6 and 16-27 without prejudice.

7. (amended) An isolated DNA encoding a fusion protein comprising a hek-L polypeptide that binds hek, and an Fc polypeptide, wherein said hek-L comprises an amino acid sequence that is at least 80% identical to a sequence selected from the group consisting of amino acids 1-202 of SEQ ID NO:2 and amino acids 1-160 of SEQ ID NO:4.

15. (amended) A process for preparing a hek L polypeptide fusion protein, comprising culturing a host cell transformed with a vector according to claim 11 under conditions promoting expression of hek L said fusion protein, and recovering said fusion protein the hek=L polypeptide from the culture.